Please enable Javascript
Cecilia Brown
Articles by Cecilia Brown
KMT2A Rearrangement in AML Linked with Early Mortality, Increased Risk of Bleeding
Cecilia Brown
Acute Myeloid Leukemia
|
March 23, 2023
The 60-day mortality rate was around twice as high in patients with KMT2A rearrangement.
Read More
NPM1 Mutational Status has ‘Minimal Impact’ on Prognosis in Relapsed, Refractory AML
Cecilia Brown
Acute Myeloid Leukemia
|
March 23, 2023
While NPM1 mutations impacted CR rates, they had “no impact” on RFS and OS after each line of salvage therapy.
Read More
ZUMA-7 Data Show Axicabtagene Ciloleucel Improves OS Over Standard of Care in LBCL
Cecilia Brown
Aggressive B-Cell Lymphoma
|
March 22, 2023
Axicabtagene ciloleucel showed a significant improvement in OS over standard of care in relapsed or refractory LBCL.
Read More
Sandy Wong, MD, on Advances in Myeloma Treatment
Sandy Wong, MD
Myeloma
|
March 22, 2023
Novel therapies and “game-changing drugs” have made a major impact on the treatment of myeloma, Dr. Wong said.
View More
Clinical Progression Outcomes ‘Inferior’ to Biochemical Progression Outcomes in Multiple Myeloma
Cecilia Brown
Myeloma
|
March 22, 2023
Patients with clinical progression had a significantly shorter median OS from their first relapse.
Read More
First-in-Human Study of Revumenib Shows ‘Promising’ Activity in Acute Leukemias
Cecilia Brown
Acute Myeloid Leukemia
|
March 21, 2023
Revumenib is a potent, selective oral inhibitor of interaction between menin and KMT2A.
Read More
Translational Study Suggests Rationale for Targeting CXCL8/CXCR2 Pathway in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
March 21, 2023
Hematopoietic stem/progenitor cells from patients with myelofibrosis are “enriched” for a CXCL8/CXCR2 gene signature.
Read More
MRD Negativity Linked with ‘Improved Outcomes’ in AML, Regardless of Treatment Intensity
Cecilia Brown
Acute Myeloid Leukemia
|
March 21, 2023
A new study suggests CR with MRD negativity should be the “key objective" of high- and low-intensity therapy for AML.
Read More
Sandy Wong, MD, on Raising Myeloma Awareness
Sandy Wong, MD
Myeloma
|
March 20, 2023
Sandy Wong, MD, explains how clinicians and researchers can help educate others about myeloma.
View More
Pelabresib Plus Ruxolitinib ‘Well-Tolerated’ in Myelofibrosis
Cecilia Brown
Myelofibrosis
|
March 16, 2023
A reduction in spleen volume reduction of ≥35% at 24 weeks occurred in 68% of patients.
Read More
Developing Second Malignancy Post-AHSCT Linked with Poor PFS, OS in Multiple Myeloma
Cecilia Brown
Myeloma
|
March 15, 2023
Around two-thirds of second primary malignancies were solid malignancies and 20% were myeloid malignancies.
Read More
Sandy Wong, MD, on the Meaning of Myeloma Awareness Month
Sandy Wong, MD
Myeloma
|
March 14, 2023
Sandy Wong, MD, explains what Myeloma Awareness Month means to her as a clinician and a researcher.
View More
Ixazomib-Based Therapy Shows PFS Benefit in Multiple Myeloma ‘Regardless of Cytogenetic Status’
Cecilia Brown
Myeloma
|
March 14, 2023
The “greatest benefit" was observed in those who had t(4;14) or amp1q21.
Read More
Bispecific CAR-T Targeting CD19, CD20 Is ‘Safe and Efficacious’ in Relapsed, Refractory MCL
Cecilia Brown
Mantle Cell Lymphoma
|
March 13, 2023
A phase I/II trial of LV20.19 showed a 100% ORR in patients with relapsed or refractory MCL.
Read More
Rituximab Maintenance ‘Benefits’ Older Patients with MCL Who Do Not Undergo AHSCT
Cecilia Brown
Mantle Cell Lymphoma
|
March 13, 2023
Benefits of rituximab maintenance were observed despite the shift in first-line induction strategies over the years.
Read More
‘Frailty’ Definition, Prevalence, Impact Varies in Multiple Myeloma Clinical Trials
Cecilia Brown
Myeloma
|
March 10, 2023
Frailty measures have been "increasingly incorporated" in multiple myeloma trials in recent years.
Read More
Brexucabtagene Autoleucel Efficacy, Toxicity in MCL ‘Consistent’ with ZUMA-2 Data
Cecilia Brown
Mantle Cell Lymphoma
|
March 7, 2023
Brexucabtagene autoleucel in the standard-of-care setting for R/R MCL showed efficacy and toxicity “consistent” with ...
Read More
Lower-Risk MDS Treatment Remains an 'Unmet Need'
Cecilia Brown
Myelodysplastic Syndromes
|
March 6, 2023
Treatment of LR-MDS remains an unmet need and goals of therapy should extend beyond transfusion independence.
Read More
Get to Know … Noopur Raje, MD
Cecilia Brown
Myeloma
|
March 6, 2023
Dr. Raje reflects on the mentors who shaped her career, the evolution of myeloma treatment, and more.
Read More
Carfilzomib-Based Regimens are ‘Effective Strategies’ in Standard, High-Risk Multiple Myeloma
Cecilia Brown
Myeloma
|
March 6, 2023
The four-year OS rate from the first randomization was 94% in patients without high-risk cytogenetic abnormalites.
Read More
Load More